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Epigenetic regulation is an important factor in glucose metabolism, but underlying 2 5 mechanisms remain largely unknown.
Here we demonstrated that 2 6 bromodomain-containing proteins (Brds), transcriptional regulators binding to acetylated 2 7 histone, are potent modulators of glucose metabolism via the gut-liver farnesoid X 2 8 receptor (FXR)-fibroblast growth factor 15/19 (FGF15/19) pathway. In vivo inhibition of 2 9
Brd4 by the inhibitor JQ1 in mice strongly inhibited ileal expression of FGF15, resulting 3 0 in decreased FGFR4-related signaling, increased glucose production in the liver and 3 1 hyperglycemia. Adverse metabolic effects of BRD4 inhibition were reversed by 3 2 overexpression of FGF19, with improvement in hyperglycemia. At a cellular level, we 3 3 demonstrate that BRD4 binds to the promoter region of FGF19 in human intestinal cells; 3 4 BRD inhibition by JQ1 reduces binding to the FGF19 promoter and downregulates 3 5 FGF19 expression. Thus, we identify Brd4 as a novel transcriptional regulator of 3 6
intestinal FGF15/19 in ileum, and a contributor to hepatic and systemic glucose 3 7 metabolism. 3 8
Introduction 4 2
Type 2 diabetes (T2D) is a complex disorder influenced by interactions between 4 3 multiple genetic loci and environmental factors (Pinney and Simmons, 2010) . 4 4
Environmental factors contributing to metabolic disease, such as intrauterine 4 5 environment, diet and physical activity, may mediate risk via epigenetic mechanisms, 4 6 such as DNA methylation, histone modification, and noncoding RNAs. Given that 4 7 epigenetic mediators are influenced by metabolic signals and in turn modulate 4 8
transcriptional and/or developmental responses, understanding mechanisms by which 4 9 epigenetic signals influence metabolic disease risk is a key scientific challenge. 5 0
One key epigenetic mark is histone acetylation, which mediates chromatin accessibility 5 1 to transcriptional factors and coactivators (Verdin and Ott, 2015) . In turn, histone 5 2 acetylation is mediated by histone acetyltransferase (HAT) and removed by histone 5 3 deacetylase (HDAC). Modulation of histone acetylation can alter systemic metabolism.
4
For example, mice with heterozygous deficiency of the HAT CREB-binding protein 5 5 (CBP), remain insulin sensitive, despite lipodystrophy (Yamauchi et al., 2002) .
6
Conversely, deletion of HDAC in skeletal muscle increases lipid oxidation, energy 5 7 expenditure and insulin resistance (Gaur et al., 2016; Hong et al., 2017) . Together, 5 8 these data demonstrate that histone acetylation plays an important role in energy 5 9 therefore asked whether this was related to impaired insulin action or cell autonomous 1 1 4 insulin resistance. Hepatic insulin action in vivo, as measured by Akt phosphorylation 1 1 5 (Figure S1A-C) did not differ. Moreover, basal glucose production in primary 1 1 6 hepatocytes did not differ with JQ-1, and the effect of insulin to suppress glucose 1 1 7 production was only modestly reduced (vehicle vs. JQ-1, p = 0.05, Figure S1D ). 1 1 8
Together, these data suggested that reduction in systemic insulin sensitivity or cell 1 1 9 autonomous hepatic insulin action was not likely the dominant mediator of in vivo 1 2 0 hyperglycemia. 1 2 1 1 2 2
JQ-1 alters hepatic gene expression and sterol metabolism 1 2 3
To identify potential molecular mediators of fasting hyperglycemia in vivo, we analyzed 1 2 4 gene expression in the liver using microarray. 1471 genes were upregulated and 1036 1 2 5 genes were downregulated by JQ-1 (FDR<0.25). Pathway analysis using Gene Set 1 2 6
Enrichment Analysis (GSEA) and REACTOME pathways (Table S1) revealed 1 2 7 upregulation of multiple pathways related to glucose production and lipid metabolism 1 2 8 (biosynthesis of triglycerides, fatty acids, and cholesterol; β -oxidation) in JQ-1-treated 1 2 9 mice (Figure S1E, F). Analysis of individual genes revealed increased expression of 1 3 0 genes related to gluconeogenesis (fold change vs. vehicle: Pepck: 1.6 ± 0.2, p < 0.01, 1 3 1 G6pase: 2.0 ± 0.6, Figure S1G , H). Effects on lipid metabolism were more striking, 1 3 2 with significant increases in expression of genes regulating FA synthesis (Acc: 1.9 ± 0.2, 1 3 3 p < 0.01; Fasn 2.2 ± 0.3, p < 0.01), β -oxidation (Pparα: 1.6 ± 0.1, p < 0.01; Cpt1α: 1.2 ± 1 3 4 0.0, p < 0.01), and cholesterol synthesis (e.g. Hmgcr, Hmgcs1, and Srebp2) ( Figure  1 3 5 S1I-O). 1 3 6
Given these prominent patterns of lipid-related gene expression in JQ-1 treated mice, 1 3 7
we analyzed plasma and hepatic lipids. There were no differences in either plasma or 1 3 8 hepatic triglycerides (Figure S2A, B) . By contrast, cholesterol levels were reduced by 1 3 9 52% in plasma (p<0.05), with 28% reduction in liver content in JQ-1-treated mice 1 4 0 (plasma: veh; 165 ± mg/dl, JQ-1; 79 ± 29 mg/dl, p < 0.05; liver: veh; 0.94 ± 0.1 mg/g 1 4 1 tissue, JQ-1; 0.68 ± 0.1 mg/g tissue, p < 0.05) (Figure S2C, D) . 1 4 2
Reductions in both plasma and tissue cholesterol levels, despite significantly increased 1 4 3 expression of cholesterol synthetic genes, suggested that cholesterol catabolic 1 4 4 pathways, such as bile acid metabolism, may be upregulated. Indeed the major 1 4 5 enzymes of both classic and alternative bile acid synthesis pathways were upregulated 1 4 6 by JQ-1, with a 1.4-fold increase in the rate-limiting enzyme Cyp7a1 (p = 0.08) and Luminal bile acids are transported into enterocytes by ASBT (Slc10a2), where they 1 7 0 can bind to FXR and activate its transcriptional activity to increase expression of its 1 7 1 targets including Fgf15, Shp, Slc15a and Slc51b (Wong et al., 2011) . While there was 1 7 2 no change in no change in Slc10a2, Tgr5, Fxr, or RXRa expression in ileum of 1 7 3 JQ-1-treated mice (not shown), we observed profound alterations in expression of FXR 1 7 4 target genes. Expression of Fgf15 and Shp was reduced by 90% and 95% (p<0.01 for 1 7 5 all), with similar trend for Slc51a and Slc51b (Figure 2E-H) . In agreement, plasma 1 7 6 FGF15 was decreased by 29% in JQ-1-treated mice (veh; 2.1 ± 0.1 ng/ml, JQ-1; 1.4 ± 1 7 7 0.1 ng/ml, p < 0.05) ( Figure 2I ). 1 7 8
We next evaluated potential mechanisms mediating JQ-1 decreases in Fgf15 of other cell type markers for enterocytes (keratin 20 (Krt20)), enteroendocrine cells 1 9 0 (hepatocyte nuclear factor (HNF) 1α), neuroendocrine cells (chromogranin A (ChgA)), 1 9 1 goblet cells (mucin 2 (Muc2)), stem cells (leucine-rich orphan G-protein-coupled 1 9 2 receptor 5 (Lgr5)), or intestinal neuroendocrine peptides (Gcg or Pyy), suggesting 1 9 3 JQ-1-mediated reduction in Fgf15 expression was not related to global alterations in cell 1 9 4 type distribution (Figure S3B-J). 1 9 5 1 9 6
JQ-1 inhibits Brd4 binding to the Fgf15 promoter in HT-29 cells 1 9 7
Marked downregulation of ileal expression of Fgf15 in JQ-1 treated mice suggested 1 9 8 that the bile acid-Fgf15 feedback loop might play a prominent role in systemic metabolic 1 9 9 effects of JQ-1. To test this hypothesis at a cellular level, we utilized the human intestinal 2 0 0 cell line HT-29, which constitutively expresses FGF19 at a high level (Vergnes et al., 2 0 1 2013). HT-29 cells were treated with 500 nM JQ-1 for 24 hours. While there was no 2 0 2 change in BRD4 expression ( Figure 3A) , expression of the Brd4 target gene MYC was 2 0 3 reduced by 83% with JQ-1 (p < 0.01), as predicted ( Figure 3B) . In parallel, expression 2 0 4 of FGF19 was reduced by 96% (p < 0.01) with similar dramatic reduction in SHP (89% 2 0 5 reduction, p < 0.01) (Figure 3C, D) . There was no change in FXR or SLC51B 2 0 6 expression (data not shown), consistent with prior evidence indicating BRD4 does not 2 0 7 bind to FXR or SLC51B (GSE73319 (McCleland et al., 2016) and ENCSR514EOE 2 0 8 (Consortium, 2012). Moreover, secretion of FGF19 into culture medium was completely 2 0 9
abolished by JQ-1, with >98% decrease in the conditioned medium (p<0.01, Figure 3E ). 2 1 0
To determine whether JQ-1 mediated reduction in expression of FGF19 and SHP was 2 1 1 mediated by modulation of BRD4 binding to promoter regions of these genes, we 2 1 2 performed ChIP-PCR analysis using an anti-BRD4 antibody ( Figure 3F ) (Rathert et al., 2 1 3 2015). As expected, BRD4 bound to its target Myc (control); Brd4 also bound robustly to 2 1 4 promoter sequences of both FGF19 and SHP (Figure 3G, H) . This was markedly 2 1 5 inhibited by JQ-1, with a >90% reduction in binding (Figure 3G, H) . 2 1 6 2 1 7
Overexpression of FGF19 reverses glucose intolerance induced by JQ-1 2 1 8
To determine the requirement for FGF15/19 signaling in mediating the metabolic 2 1 9 effects of JQ-1, we treated mice with AAV-FGF19 or GFP control vectors, and then 2 2 0 treated mice with JQ-1 (25 mg/kg, ip) for 10 days (Figure 4A) . Plasma FGF19 was not 2 2 1 detectable in AAV-GFP controls, but was readily detected in plasma of AAV-FGF19 mice 2 2 2 ( Figure 4B) . Consistent with prior studies (Lan et al., 2017; Morton et al., 2013) , 2 2 3 AAV-FGF19-treated mice had lower body weight and blood glucose levels at baseline 2 2 4 ( Figure 4C ) but weight did not change during JQ-1 treatment in either GFP or FGF19 2 2 5 groups ( Figure 4C) . As with prior cohorts, JQ-1 increased blood glucose in AAV-GFP 2 2 6 control mice as early as 4 days after the onset of treatment, but this effect was not 2 2 7 observed in AAV-FGF19 mice. Glucose tolerance testing at day 10 of treatment again 2 2 8 revealed significant impairment in JQ-1 treated mice (35% increase in glucose AUC, p < 2 2 9 0.01) ( Figure 4D) . By contrast, the ability of JQ-1 to impair glucose tolerance was fully 2 3 0 reversed in mice overexpressing FGF19 (Figure 4D, E) . Moreover, overexpression of 2 3 1 FGF19 reduced both basal and glucose-stimulated insulin levels (Figure 4F) , indicating 2 3 2 FGF19-mediated reversal of glucose tolerance in JQ-1 treated mice is 2 3 3 insulin-independent. Our studies identify the intestinal Fgf15/19 hormonal axis as a target of epigenetic 2 3 7 and transcriptional regulation by the bromodomain protein Brd4 and its inhibitor JQ-1. 2 3 8
We demonstrate that pharmacological inhibition of Brd4 induces hyperglycemia and 2 3 9 impaired glucose tolerance in mice, via inhibition of intestinal FGF15 expression and 2 4 0 reduced Fgfr4-mediated signaling in liver. ChIP-PCR analysis revealed that FGF19 and 2 4 1 SHP are novel targets of Brd4 in intestine, and that JQ-1 reduced Brd4 binding to the 2 4 2 promoter of these targets, reduced their expression, and reduced secretion of FGF19. Given that the effects of JQ-1 in primary hepatocytes were small in magnitude, cell 2 8 9 autonomous effects in the liver do not appear to be dominant. Rather, JQ-1 mediated 2 9 0 repression of intestinal FGF15 expression, secretion, and signaling drives in vivo 2 9 1 systemic and hepatic glucose metabolism, as demonstrated by reversal of 2 9 2 hyperglycemia with restoration of systemic Fgf19 levels. 2 9 3
We acknowledge that JQ-1 may have additional Fgf15/19-independent effects. 2 9 4
Neither systemic insulin tolerance nor hepatic insulin signaling were affected by 2 9 5 short-term treatment with JQ-1, indicating insulin resistance was not a major contributor 2 9 6
to hyperglycemia despite prior reports of Brd4 effects on adipogenesis and myogenesis 2 9 7 (Lee et al., 2017). While there were no differences in pancreatic islet size or insulin 2 9 8 staining, glucose-stimulated insulin levels were lower in JQ-1-treated mice. While 2 9 9 BRD4 can modulate senescence-associated genes in islets in the setting of In summary, inhibition of the bromodomain protein Brd4 by JQ-1 inhibits FGF15 3 0 6 and SHP expression in ileum, resulting in reduced FGFR signaling in liver, altered sterol 3 0 7 metabolism, increased gluconeogenesis, and hyperglycemia. Effects of JQ-1 on 3 0 8 glucose metabolism were FGF15/19 dependent, as overexpression of FGF19 reversed 3 0 9 hyperglycemia induced by JQ-1. Thus, our studies identify FGF15/19 as a hormonal 3 1 0 target of epigenetic regulation potently contributing to systemic metabolic control. We gratefully acknowledge grant support from NIH DK106193 (to MEP), R01DK101043 3 1 4 (to LG), R01CA142106 and R01HD093540 (to JQ), and DK036836 (Joslin DRC). CK 3 1 5 was supported by Sunstar Foundation, and SO was supported by the Prince Mahidol 3 1 6
Award Foundation. We also thank NGM for providing adenoviral FGF19 and GFP. Glucose tolerance was assessed after intraperitoneal injection of glucose (1 or 2 g/kg 3 2 7 body weight after a 16 hour fast. Blood glucose was measured via tail vein sampling at 3 2 8 the indicated time points. Insulin tolerance was assessed after intraperitoneal injection 3 2 9 of human insulin (0.5 units/kg body weight, Lilly) after a 4-hour fast. Plasma insulin and 3 3 0 glucagon were measured using an enzyme-linked immunosorbent assay (ELISA) kit 3 3 1 (Crystal Chem and R&D, respectively). Plasma triglyceride (TG) and total cholesterol 3 3 2 were measured using colorimetric assays (Cayman Chemical and Cell Biolabs). 3 3 3
In vivo treatment with the bromodomain inhibitor JQ-1 3 3 4
The Brd4 inhibitor JQ1 was synthesized and purified in the laboratory of Dr. Jun Qi 3 3 5 (DFCI). For in vivo experiments, a stock solution (50 mg/mL in DMSO) was diluted to a 3 3 6 1 working concentration of 5 mg/mL in 10% hydroxypropyl β -cyclodextrin (Sigma). Mice 3 3 7
were injected at a dose of 25 or 50 mg/kg given intraperitoneally. Vehicle controls were 3 3 8
given an equal amount of DMSO in 10% hydroxypropyl β -cyclodextrin. For in vitro 3 3 9 experiments, JQ1 was dissolved in DMSO and added to cells at indicated 3 4 0 concentrations, with equal volume of DMSO as control. Quantitative real-time PCR was performed using SYBR Green (Bio-Rad, Hercules, CA, 3 5 0 USA). Expression was normalized by Rn18s (18S rRNA), Rpl13a or 36B4. Primer 3 5 1 sequences are provided in Table S2 . supplemented with 10% FBS, 1% PenStrep (ThermoFisher Scientific) in a humidified 3 7 7 atmosphere with 5% CO 2 at 37 °C. 3 7 8
Primary hepatocyte isolation and measurement of glucose production 3 7 9
Primary hepatocytes were isolated from C57BL/6 mice after liver perfusion with 3 8 0 collagenase and seeded 1 x 10 5 cells/ml into collagen coated plates containing DMEM 3 8 1 (ThermoFisher Scientific). The media were changed after 4 hours. Primary hepatocyte 3 8 2 experiments were performed the day after isolation. Glucose production in primary 3 8 3 hepatocytes was measured as preciously described (Matsumoto and Sakai, 2012) . 3 8 4
Briefly, after 6 h serum starvation with or without JQ-1 and FGF19, cells were cultured in 3 8 5 glucose and phenol red-free DMEM with or without insulin (10, 100 nM), JQ-1 (250 nM) 3 8 6 and FGF19 (100 ng/ml) for 5 h. The medium was used to determine glucose 3 8 7 concentrations with the Glucose (HK) Assay Kit (Sigma). 3 8 8
Chromatin immunoprecipitation (ChIP)-PCR 3 8 9
ChIP was performed on HT-29 cells cultured in the presence or absence of 3 9 0 JQ1 (250 nM, 24 hr). Chromatin pooled from approximately 1 x 10 6 HT-29 cells was 3 9 1 used for each immunoprecipitation. HT-29 cells were fixed directly on the dish with 1% 3 9 2 formaldehyde for 10 minutes followed by quenching with 0.125M glycine for 5 minutes. 3 9 3
Chromatin was extracted, followed by shearing on a Tekmar Sonic Disruptor (Cincinnati, 3 9 4 OH, USA) (3 cycles, 80% Amp and 6 sec pulse, 5 min on/off). The sonicated chromatin 3 9 5 was immunoprecipitated with 5 μ g of antibody (anti-BRD4, Bethyl #A301-985A). bound 3 9 6
to Dynabeads (Invitrogen) as previously described (Anand et al., 2013) . Cross-linking 3 9 7 was reversed in immunoprecipitate and input chromatin samples prior to purification of 3 9 8 genomic DNA. Target and non-target regions of genomic DNA were amplified by PCR or 3 9 9
qRT-PCR in both the immunoprecipitates and input samples using SYBR Green 4 0 0 chemistry. Enrichment was calculated as a percentage of input DNA for each sample. 4 0 1
ChIP-PCR primer sequences are shown in Table S2 . ChIP-PCR primers for MYC were 4 0 2 previously described (Rathert et al., 2015) . Data are expressed as mean ± SEM. One-way ANOVA and repeated-measures 4 1 1 ANOVA followed by multiple comparison tests (Bonferroni/Dunn method) were used 4 1 2 where applicable. Student's t-test was used to analyze the differences between two 4 1 3 groups. Differences were considered significant at P < 0.05. Ritchie, M.E., Diyagama, D., Neilson, J., van Laar, R., Dobrovic, A., Holloway, A., and 5 0 7
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